PartnershipApr 24, 2026, 08:41 AM
MeiraGTx Completes Strategic Collaboration with Hologen
AI Summary
MeiraGTx Holdings plc completed the initial closing of its strategic collaboration with Hologen Limited on April 20, 2026. This collaboration involved amendments to the existing Neuro and Manufacturing Framework Agreements and the execution of a new Collaboration and License Agreement. The partnership is focused on the research, development, manufacture, and commercialization of MeiraGTx's investigational gene therapies, including AAV-GAD for Parkinson's disease and AAV-BDNF for genetic obesity disorders.
Key Highlights
- Initial closing of strategic collaboration with Hologen Limited completed on April 20, 2026.
- Amended Neuro and Manufacturing Framework Agreements.
- Entered into a new Collaboration and License Agreement.
- Focuses on AAV-GAD for Parkinson's and AAV-BDNF for genetic obesity gene therapies.